| 0.6001 -0.004 (-0.58%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.83 | 1-year : | 0.95 |
| Resists | First : | 0.71 | Second : | 0.81 |
| Pivot price | 0.64  |
|||
| Supports | First : | 0.54 | Second : | 0.45 |
| MAs | MA(5) : | 0.6 |
MA(20) : | 0.67 |
| MA(100) : | 1.54 |
MA(250) : | 1.63 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 18.6 |
D(3) : | 18.1 |
| RSI | RSI(14): 33.3 |
|||
| 52-week | High : | 2.95 | Low : | 0.54 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CGTX ] has closed above bottom band by 27.7%. Bollinger Bands are 70.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.62 - 0.62 | 0.62 - 0.63 |
| Low: | 0.58 - 0.59 | 0.59 - 0.59 |
| Close: | 0.59 - 0.6 | 0.6 - 0.61 |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Fri, 06 Sep 2024
Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth? - Simply Wall St
Tue, 03 Sep 2024
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences - GlobeNewswire
Tue, 03 Sep 2024
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences - StockTitan
Mon, 12 Aug 2024
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q1 2024 Earnings Call Transcript - Insider Monkey
Thu, 08 Aug 2024
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update - StockTitan
Wed, 31 Jul 2024
Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 40 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 28.3 (%) |
| Shares Short | 647 (K) |
| Shares Short P.Month | 215 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.56 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -93.7 % |
| Return on Equity (ttm) | -108.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -0.65 |
| PEG Ratio | 0 |
| Price to Book value | 1.05 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|